Top Page
Physiomics
(LSE:PYC)
Physiomics (PYC) vs. iShares MSCI United Kingdom ETF (EWC)
Physiomics Business Overview & Revenue Model
Physiomics Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 953.00K | 784.00K | 543.25K | 597.35K | 830.27K | 702.31K |
| Gross Profit | -543.08K | -435.08K | -677.43K | -581.62K | -429.01K | -365.79K |
| EBITDA | -553.33K | -448.21K | -659.80K | -561.57K | -347.84K | -324.52K |
| Net Income | -485.25K | -415.25K | -609.35K | -477.26K | -253.14K | -215.83K |
Balance Sheet | ||||||
| Total Assets | 558.00K | 892.03K | 422.60K | 674.39K | 1.12M | 1.32M |
| Cash, Cash Equivalents and Short-Term Investments | 257.00K | 461.24K | 191.07K | 416.59K | 687.67K | 1.04M |
| Total Debt | 0.00 | 0.00 | 3.83K | 7.35K | 0.00 | 0.00 |
| Total Liabilities | 165.00K | 199.85K | 140.08K | 142.67K | 140.61K | 157.57K |
| Stockholders Equity | 393.00K | 692.17K | 282.53K | 531.72K | 974.81K | 1.17M |
Cash Flow | ||||||
| Free Cash Flow | -469.08K | -550.08K | -565.44K | -271.50K | -358.62K | -48.65K |
| Operating Cash Flow | -464.14K | -546.14K | -548.13K | -264.86K | -349.25K | -32.50K |
| Investing Cash Flow | -4.41K | -3.41K | -15.21K | -6.22K | -9.37K | -16.15K |
| Financing Cash Flow | 456.73K | 819.73K | 337.83K | 0.00 | 2.85K | 44.24K |
Physiomics Technical Analysis
Physiomics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £7.23M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
49 Neutral | £4.41M | -0.88 | -53.79% | ― | ― | 85.56% | |
48 Neutral | £1.41M | -0.72 | -89.43% | ― | 44.32% | 60.00% | |
45 Neutral | £10.51M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
43 Neutral | £6.09M | -2.61 | -2.42% | ― | ― | ― | |
41 Neutral | £2.45M | ― | ― | ― | 418.49% | 27.86% |
Physiomics Corporate Events
Physiomics plc has launched a revised retail equity offer via Winterflood’s Retail Access Platform to raise up to £110,000 by issuing as many as 27.5 million new shares at £0.004, matching the price of a concurrent £490,000 institutional placing. The fundraising, which follows the cancellation of a previous placing and retail offer, is aimed at giving existing UK retail shareholders the chance to participate on the same terms as institutional investors, with the new shares expected to be admitted to AIM around 20 March and ranking pari passu with existing stock.
Both the WRAP Retail Offer and the placing are conditional on admission of the new shares to trading on AIM, though the placing will proceed independently if the retail tranche does not complete. The move underlines Physiomics’ effort to diversify and deepen its investor base while securing fresh capital, but it also highlights the risks borne by small-cap investors, with the company stressing that shares are high risk, capital is at risk, and no prospectus will be published under UK public offer exemptions.
The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.44 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics has raised £490,000 through a discounted placing of 122.5 million new shares at £0.004 each and plans to launch a WRAP retail offer of up to a further £110,000 for existing shareholders on the same terms. The revised fundraising replaces an earlier cancelled placing, removes the need for a previously called general meeting and is intended to support business development, capability expansion, personalised dosing software and exploration of strategic options as the company targets another record year of income after delivering 46% revenue growth in its last financial year.
Management says long-term shareholders have backed the business at a higher price than the scrapped March offer, signalling confidence in its growth trajectory and market expectations for FY26. The fresh capital will fund expansion of consulting services, further integration of its personalised dosing tools and corporate initiatives aimed at accelerating growth in modelling and biometrics services, potentially strengthening Physiomics’ competitive position and diversifying its customer base in the pharmaceutical services market.
The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.44 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics plc has received a shareholder requisition to convene a general meeting seeking to overhaul its board, led by investor Michael Whitlow, who holds about 13.68% of the company’s share capital. The proposed resolutions would appoint four new directors and remove the existing four, amounting to a full board replacement if all motions pass.
The current board is taking legal advice to verify that the request complies with UK company law and, if valid, must call the meeting by early April with the vote to follow within 28 days of the notice. Directors, who had been in dialogue with Whitlow, publicly argue that a wholesale board change would be highly detrimental to the company and its shareholders, signalling a potentially contentious governance showdown that could reshape leadership and strategic direction.
The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.48 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics plc has completed an oversubscribed WRAP Retail Offer, raising gross proceeds of £223,279.48 through the issue of 74,426,493 new ordinary shares at the same price as a previously announced placing. Together, the retail offer and placing constitute a conditional fundraise of £673,279.36 via 224,426,453 new shares, subject to shareholder approvals at a general meeting and admission of the new shares to trading on AIM.
The company has set an expected timetable, with the general meeting scheduled for 7 April 2026 and admission of the new ordinary shares to AIM targeted for 8 April 2026. On admission, the new shares from both the placing and WRAP Retail Offer will rank pari passu with existing ordinary shares, meaning existing and new investors will hold the same class of equity once the fundraise completes.
The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.48 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics plc has launched a Winterflood Retail Access Platform offer to raise up to £49,999.98 by issuing up to 16,666,660 new ordinary shares at £0.003 each, matching the price of a concurrent institutional placing of approximately £499,999.86. The fundraising, which is subject to shareholder approval at a 7 April 2026 general meeting and admission of the new shares to AIM around 8 April, is structured to give existing UK retail shareholders the chance to participate on the same terms as placing investors, potentially broadening the shareholder base while diluting existing holdings.
The WRAP Retail Offer is open only to existing UK shareholders via participating intermediaries, with a minimum subscription of £100 and the company retaining discretion over scaling back or rejecting applications. New shares issued under the offer will rank pari passu with existing stock, and the structure utilises UK prospectus exemptions, indicating a relatively small but strategically inclusive capital raise intended to support the same objectives as the larger placing without the cost and delay of a full prospectus.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.44 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics reported record first-half total income of £528,000 for the six months to 31 December 2025, up 51% year-on-year and its highest half-year income since inception, driven by expanded Modelling and Simulation work and a new Biometrics service line. Revenue rose to £498,000 but operating losses widened to £327,000 due to hiring and temporary reliance on external contractors, while cash stood at £257,000 and shareholders’ funds at £393,000.
The company launched its Biometrics service line, hired a new Head of Biometrics and a senior quantitative pharmacology scientist, and secured 11 new contracts, including deals with longstanding client Numab Therapeutics and global health organisation GARDP. Management expects full-year 2026 income to meet market forecasts for a 27% increase versus 2025 and anticipates a 24% reduction in loss after tax, supported by better utilisation of internal staff, reduced use of external consultants, and a robust pipeline extending into 2027 including new international biopharma clients and data access for its personalised dosing software.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.63 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics plc has secured a new contract with a South Korean clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates and immuno-oncology therapies for cancer. The project, worth up to £66,600, will see Physiomics apply PK/PD modelling and simulation to guide dosing decisions for one of the client’s clinical assets, with work starting immediately and expected to complete within two months.
The mandate broadens Physiomics’ international client base and underscores its strategy of expanding into markets further afield, while highlighting the growing role of advanced quantitative modelling in de-risking oncology drug development. Management framed the win as validation of the company’s capabilities in providing data-driven insights that enhance decision-making for innovative cancer therapies at a critical clinical stage.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.46 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics plc has secured a new contract from long-standing client Numab Therapeutics AG to develop a pharmacokinetic-pharmacodynamic (PK/PD) model for a key asset in Numab’s immunology and inflammation pipeline, reinforcing its role as a specialist partner in quantitative drug development. The project, which is due to start immediately and conclude by the second quarter of 2026, will inform the target candidate profile at an early stage to support data-driven R&D decisions, deepening the companies’ collaboration and highlighting the growing reliance of next-generation antibody developers on advanced modelling to accelerate and de-risk pipeline progression.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.27 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Physiomics has granted a total of 4,548,132 share options under its existing option scheme, including a new award of 4,548,132 options to Head of Biometrics Jesse Thissen, structured across three tranches with exercise prices set at substantial premiums to the current share price and vesting between July 2026 and July 2028. The Board positions the grant as a key retention and incentive tool as the company scales its biometrics service line, which has already secured three contracts within six months of Thissen’s appointment, supporting its wider strategy to drive growth and move towards cash generation.